Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease

Kidney International

Volumn 86, Issue 6, 2014, Pages 1079-1081

  Lee, Hyun Gyu ^a   Choi, Hoon Young ^b   Bae, Jong Sup ^c  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOCAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEOGLYCAN; UNCLASSIFIED DRUG; VASCULOTROPIN;

CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; ESM 1 GENE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; KIDNEY CLEARANCE; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; RISK FACTOR;

EID: 84964285920     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.292     Document Type: Note

References (18)

1. Levey AS, Atkins R, Coresh J et al. Chronic kidney disease as a global public health problem: Approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72: 247-259.
2. Levey AS, Tangri N, Stevens LA. Classification of chronic kidney disease: A step forward. Ann Intern Med 2011; 154: 65-67.
3. Tangri N, Stevens LA, Griffith J et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011; 305: 1553-1559.
4. Rigatto C, Sood MM, Tangri N. Risk prediction in chronic kidney disease: pitfalls and caveats. Curr Opin Nephrol Hypertens 2012; 21: 612-618.
5. Yilmaz MI, Siriopol D, Saglam M et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014; 86: 1213-1220.
6. Sarrazin S, Adam E, Lyon M et al. Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006; 1765: 25-37.
7. Lassalle P, Molet S, Janin A et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulatedby cytokines. J Biol Chem 1996; 271: 20458-20464.
8. Bechard D, Meignin V, Scherpereel A et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000; 37: 417-425.
9. Lee W, Ku SK, Kim SW et al. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol 2014; 229: 620-630.
10. Scherpereel A, Depontieu F, Grigoriu B et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006; 34: 532-537.
11. Tsai JC, Zhang J, Minami T et al. Cloning and characterization of the human lung endothelial-cell-specific molecule-1 promoter. J Vasc Res 2002; 39: 148-159.
12. Abid MR, Yi X, Yano K et al. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 2006; 72: 136-145.
13. Kim JH, Park MY, Kim CN et al. Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1alpha in human colon carcinoma: impact of ESM-1 on prognosis and its correlation with clinicopathological features. Oncol Rep 2012; 28: 1701-1708.
14. Li S, Wang L, Wang C et al. Detection on dynamic changes of endothelial cell specific molecule-1 in acute rejection after renal transplantation. Urology 2012; 80: 738.e1-738.e8.
15. Filep JG. Endocan or endothelial cellspecific molecule-1: A novel prognostic marker of sepsis? Crit Care Med 2006; 34: 574-575.
16. Balta S, Mikhailidis DP, Demirkol S et al. Endocan-a novel inflammatory indicator in newly diagnosed patients with hypertension: A pilot study. Angiology (advance online publication, 8 January 2014; doi:10.1177/0003319713513492).
17. Ozaki K, Toshikuni N, George J et al. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer 2014; 5: 221-230.
18. Stuveling EM, Hillege HL, Bakker SJ et al. C-reactive protein is associated with renal function abnormalities in a nondiabetic population. Kidney Int 2003; 63: 654-661.